Tirzepatide Research for Weight Loss
An evidence-based overview of research examining Tirzepatide in the context of weight loss. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tirzepatide has demonstrated the highest weight loss of any approved medication in clinical trials. The SURMOUNT-1 trial showed 22.5% mean weight loss at the highest dose (15mg) versus 2.4% with placebo at 72 weeks (N=2,539). The dual GIP/GLP-1 mechanism provides enhanced weight loss compared to GLP-1-only drugs. The head-to-head SURMOUNT-5 trial showed tirzepatide achieved 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. Over 60% of participants achieved 20% or greater weight loss, approaching surgical levels of efficacy. FDA approval for chronic weight management (Zepbound) came in November 2023.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Weight Loss
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Tirzepatide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.